Please assess the completion status of the following clinical trial:

Trial Title: Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Provision of signed and dated informed consent form (ICF)~* ≥18 years old~* Diagnosis of r/r AML~* Subjects with CD33 positive leukemia cells~* Eastern Cooperative Oncology Group (ECOG) performance status ≤1~* Adequate organ function as defined in the protocol~* Donor specific antibody (DSA) to QN-023a: MFI \<= 2000~Key Exclusion Criteria:~* Allergic to drug used in this study~* Accept other anti-tumor drug within certain time of day 0 (first QN-023a dose infusion), time window and drug defined in the protocol.~* received systemic immunosuppressive therapy within 7 days of day 0, or likely to require systemic immunosuppressive therapy~* Acute Promyelocytic Leukemia (APL)~* Active central nervous system Leukemia.~* Uncontrolled, active clinically significant infection~* Clinically significant cardiovascular disease as defined in the protocol~* Known HIV infection, active Hepatitis B (HBV) or Hepatitis C (HCV) infection~* History of central nervous system (CNS) disease such as stroke, epilepsy.~* Females are pregnant or lactating~* Investigator-assessed presence of any medical or social issues that are likely to interfere with study conduct or may cause increased risk to subject

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- QN-023a (Type: EXPERIMENTAL): QN-023a in adult subjects with r/r AML

Based on this trial design, predict the completion outcome and termination type (if applicable).